Bayer's Twin Engines: Japanese Regulatory Wins and a Settled Legal Calendar Reshape the Investment Case

Bayer files Kerendia in Japan, gets Hyrnuo approval; Roundup settlement hearing set for Sept 14. Q2 pharma sales surge 80%.

The narrative around Bayer has quietly shifted. For years, the stock was a referendum on glyphosate litigation; now, it is increasingly a bet on whether the pharmaceuticals division can deliver the growth that older blockbusters, facing patent cliffs, no longer can. That transition has been sharpened by a remarkable fortnight of regulatory activity in Japan, where the Leverkusen-based group has filed for approval of Kerendia (finerenone) in chronic kidney disease unrelated to diabetes, just days after securing a green light for Hyrnuo (sevabertinib) in HER2-mutated non-small cell lung cancer.

The Kerendia submission rests on positive Phase-III data from the FIND-CKD study, and the drug's commercial trajectory is already commanding attention. In the second quarter of 2026, the medicine generated EUR 329 million in sales, a year-on-year surge of 80 percent. Management has reaffirmed guidance that full-year revenue for the product will breach the EUR 1 billion threshold. That would establish Kerendia as a genuine growth pillar, though skeptics note that an 80 percent jump from a relatively modest base is easier to achieve than sustaining such momentum as the comparison period expands.

A Legal Front That Has Quieted — For Now

While the pharma pipeline grabs headlines, the legal calendar has also moved in Bayer's favor. On Thursday, the Eighth Circuit Court of Appeals in the US turned down a plaintiffs' bid to shift jurisdiction over the proposed $7.25 billion Roundup settlement to a federal court. The case remains in Missouri, where the final approval hearing is set for September 14.

That date is now the clearest near-term catalyst. A favorable outcome would further reduce the legal overhang and allow investors to focus more squarely on the operational story. Yet the hearing is a procedural milestone rather than a definitive victory — the settlement's final approval is not guaranteed, and further appeals or delays could re-extend the period of uncertainty. The Supreme Court's ruling in Bayer's favor in early July regarding cancer warning labels on glyphosate products has already chipped away at the risk premium, but the September hearing will determine how much of that discount is permanently retired.

Crop Science: The Quiet Stabilizer

Beneath the pharma and legal narratives, the agriculture division continues to provide ballast. The group's partnership with French seed breeder RAGT to develop hybrid wheat varieties for Europe and the US underscores a strategic push to defend its position in the global seed market. Bayer maintains that it retains market leadership in corn herbicides and seeds, and the division's contribution — organic group sales growth of 2.2 percent in the second quarter — positions it as a reliable cash generator even if it rarely moves the needle on sentiment.

Group-level adjusted EBITDA rose 1.9 percent to EUR 2.1 billion in the second quarter, and the full-year outlook was left unchanged. Meanwhile, the consumer health division has been operating under a reshaped leadership team since the summer, following a series of management changes announced in June that included new global heads for marketing, insights and analytics, commercial operations, and a new president for the US business.

Reading the Tape

The share price tells a story of cautious optimism. At Friday's close of EUR 48.66, the stock was up 0.4 percent on the day and 1.4 percent over the week. Over twelve months, it has appreciated by 74 percent, and it trades roughly 18 percent above its 200-day moving average of EUR 41.29 — evidence that the market has already priced in a meaningful improvement in the risk profile.

Still, the shares sit about ten percent below the 52-week high of EUR 53.86 reached in early July. The relative strength index stands at a neutral 53.5, suggesting the stock is neither overbought nor oversold. The gap to the high implies that a portion of the good news is already reflected in the valuation, leaving limited room for disappointment. If the September 14 hearing in Missouri falters, or if Japanese regulators request additional data on Kerendia, the risk premium could be re-applied quickly.

For now, the constellation of factors — two Japanese regulatory advances, a stabilized legal timeline, and a pharma product with genuine momentum — paints a picture of a company making progress on multiple fronts simultaneously. The question is whether that progress compounds into a structural re-rating, or whether the market has already paid for the good news in advance. The answer begins to take shape on September 14.